Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing

You may also be interested in...

China State FDA Urges Manufacturers To Abandon Some Projects Ahead Of GMP Implementation - DIA China Conference

BEIJING - China's new good manufacturing practices guidelines for pharmaceuticals officially came into effect March 1, and China's State FDA is now trying to educate domestic companies on how they can implement the new standards. One bit of advice being offered is: "Give up.

Pfizer Looks To Team Up With Shanghai Pharmaceutical To Co-develop And Commercialize Pfizer Products In China

SHANGHAI - The world's largest pharmaceutical company Pfizer Inc. and China's second-largest distributor Shanghai Pharmaceutical Holdings Co. Ltd announced April 21 a memorandum of understanding to explore business opportunities, including the potential to jointly register, commercialize and distribute in China an innovative compound from Pfizer

China's Contract Manufacturing Growth Tied To Losses In The West

SHANGHAI - China's contract manufacturing market, the world's largest supplier of bulk drug materials, is expected to reach a value of roughly $2 billion in FY2010, according to consulting firm Frost & Sullivan

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts